A detailed history of Group One Trading, L.P. transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 30,162 shares of BTAI stock, worth $17,795. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,162
Holding current value
$17,795
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.53 - $1.34 $15,985 - $40,417
30,162 New
30,162 $18,000
Q3 2023

Nov 09, 2023

BUY
$2.49 - $11.85 $95,984 - $456,793
38,548 New
38,548 $97,000
Q1 2023

May 12, 2023

SELL
$17.7 - $33.24 $527,778 - $991,150
-29,818 Reduced 98.71%
390 $7,000
Q4 2022

Feb 09, 2023

BUY
$10.25 - $22.43 $309,632 - $677,565
30,208 New
30,208 $648,000
Q2 2022

Aug 11, 2022

SELL
$9.03 - $21.55 $44,653 - $106,564
-4,945 Reduced 50.54%
4,840 $64,000
Q1 2022

May 12, 2022

BUY
$15.0 - $22.83 $84,375 - $128,418
5,625 Added 135.22%
9,785 $205,000
Q4 2021

Feb 11, 2022

SELL
$20.12 - $35.09 $156,553 - $273,035
-7,781 Reduced 65.16%
4,160 $85,000
Q3 2021

Nov 12, 2021

SELL
$23.84 - $32.03 $39,002 - $52,401
-1,636 Reduced 12.05%
11,941 $362,000
Q2 2021

Aug 10, 2021

SELL
$29.06 - $38.83 $124,928 - $166,930
-4,299 Reduced 24.05%
13,577 $395,000
Q1 2021

May 12, 2021

SELL
$39.04 - $64.6 $50,752 - $83,979
-1,300 Reduced 6.78%
17,876 $772,000
Q4 2020

Feb 10, 2021

SELL
$42.46 - $56.58 $427,444 - $569,590
-10,067 Reduced 34.43%
19,176 $886,000
Q3 2020

Nov 12, 2020

BUY
$37.44 - $64.63 $175,144 - $302,339
4,678 Added 19.04%
29,243 $1.27 Million
Q2 2020

Aug 13, 2020

SELL
$17.62 - $58.71 $201,167 - $670,292
-11,417 Reduced 31.73%
24,565 $1.3 Million
Q1 2020

May 13, 2020

BUY
$12.26 - $41.14 $441,139 - $1.48 Million
35,982 New
35,982 $804,000

Others Institutions Holding BTAI

About BioXcel Therapeutics, Inc.


  • Ticker BTAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,022,500
  • Market Cap $16.5M
  • Description
  • BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...
More about BTAI
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.